FDA Approves Asundexian as the First Factor XIa Inhibitor for Secondary Stroke Prevention
Bayer's Sunharbo cut recurrent ischemic stroke from 8.4 to 6.2 percent, or one stroke prevented per 46 treated by our math. It is not approved for AF.
Idea in Brief
The Approval
On Nov. 9 the FDA approved asundexian 50 mg daily with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA, the first factor XIa inhibitor cleared in the United States.
The Evidence
In OCEANIC-STROKE (12,327 patients), ischemic stroke occurred in 6.2 percent on asundexian and 8.4 percent on placebo (HR 0.74), with major bleeding at 1.9 and 1.7 percent.
The Caveats
Bleeding was higher in patients older than 75 and in the first 90 days, the drug is not approved in atrial fibrillation, and a rival, milvexian, reports its stroke trial next.
The Food and Drug Administration on Nov. 9 approved asundexian (Sunharbo, Bayer), a once-daily 50 mg tablet taken with antiplatelet therapy to lower the risk of another stroke after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
It is the first factor XIa inhibitor cleared in the United States, according to the FDA's announcement. China's approval of the same drug, under the same brand name, was reported on Oct. 26, 14 days earlier. For American neurologists, hospitalists and primary care physicians, the practical question is narrower than the class hype: which patients leaving a stroke unit qualify, and what an added anticoagulant buys them in absolute terms.
What did OCEANIC-STROKE show?
Asundexian cut recurrent ischemic stroke by about a quarter without a statistically significant rise in major bleeding. The phase 3 trial, OCEANIC-STROKE (NCT05686070), randomized 12,327 adults at 702 sites within 72 hours of symptom onset to asundexian 50 mg daily or placebo on top of single or dual antiplatelet therapy. The results were published in the New England Journal of Medicine on April 15 after a February presentation at the International Stroke Conference.
Ischemic stroke occurred in 6.2 percent of the asundexian group and 8.4 percent of the placebo group over a median follow-up of 567 days, a hazard ratio of 0.74 (95% CI, 0.65 to 0.84), according to the American College of Cardiology's summary. Major bleeding, the primary safety outcome, occurred in 1.9 percent and 1.7 percent (HR 1.10; 95% CI, 0.85 to 1.44). Disabling or fatal stroke fell from 3.0 percent to 2.1 percent (HR 0.69; 95% CI, 0.55 to 0.87), Cleveland Clinic reported from the trial presentation.
The population was typical of a stroke unit. Mean age was 68, about two-thirds of participants were men, and nearly 63 percent were on dual antiplatelet therapy at entry. Ninety-five percent had an ischemic stroke rather than a TIA. Large-artery atherosclerosis accounted for 43 percent of index strokes, small-vessel occlusion for 23 percent and undetermined cause for 30 percent, according to the same Cleveland Clinic report, which said the benefit was consistent across the subgroups analyzed.
What does that mean in absolute numbers?
Our arithmetic from the published rates: the 2.2 percentage-point difference in ischemic stroke means about 46 patients treated for the trial's median follow-up of roughly 19 months to prevent one recurrent ischemic stroke. The 0.9-point difference in disabling or fatal stroke works out to about 111 patients treated to prevent one such event.
On the bleeding side, the 0.2-point difference in major bleeding would mean one additional major bleed for every 500 patients treated, but that difference was not statistically significant and its confidence interval runs from a lower to a higher risk. These are crude calculations from cumulative event proportions, not time-to-event estimates, and patients in a clinic will not match the trial's mix exactly. They are a starting point for a conversation at discharge, not a substitute for the label.
Asundexian adds a modest absolute benefit to aspirin or dual antiplatelet therapy. Its value in practice will depend on keeping it away from the patients the label excludes.
Clinical Pearls
- OCEANIC-STROKE randomized 12,327 patients within 72 hours of stroke or high-risk TIA onset to asundexian or placebo on top of single or dual antiplatelet therapy.
- Ischemic stroke: 6.2 percent vs 8.4 percent over a median 567 days (HR 0.74; 95% CI, 0.65 to 0.84).
- Major bleeding: 1.9 percent vs 1.7 percent (HR 1.10; 95% CI, 0.85 to 1.44); gastrointestinal bleeding was more common on asundexian.
- By our arithmetic, about 46 patients treated for roughly 19 months prevent one recurrent ischemic stroke.
- Not recommended with combined P-gp and strong CYP3A4 inducers such as carbamazepine, or in moderate or severe hepatic impairment.
- Hold for at least 24 hours before elective procedures and for at least 24 hours after thrombolysis.
What does the label restrict?
The FDA's summary of the prescribing information lists several limits that will matter at the bedside. Overall major bleeding was similar to placebo, but it was higher with asundexian in patients older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding was more common. Diarrhea was the most frequent adverse reaction, in 3 percent or more of patients.
The drug is not recommended with medicines that are combined P-glycoprotein and strong CYP3A4 inducers, such as carbamazepine, which may reduce its effect, and it is not recommended in moderate or severe hepatic impairment. It should be withheld for at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis for acute ischemic stroke. It is not approved for stroke prevention in atrial fibrillation, the FDA said.
The application had Fast Track and Priority Review designations. “Today’s approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention,” Hylton V. Joffe, director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research, said in the announcement. Neither the FDA nor the other sources we reviewed gave a U.S. list price.
Why is atrial fibrillation excluded?
Because the drug already failed there. Bayer stopped OCEANIC-AF on Nov. 19, 2023, on the recommendation of its independent data monitoring committee, after interim results showed inferior efficacy of asundexian compared with apixaban. That trial had enrolled 14,830 patients before it was terminated, according to its ClinicalTrials.gov record.
By our count, 1,086 days passed between that stop and the Nov. 9 approval. The drug survived because the stroke trial asked a different question. OCEANIC-AF tested whether a factor XIa inhibitor could stand in for a full-dose anticoagulant in atrial fibrillation. OCEANIC-STROKE tested whether one adds anything to antiplatelet therapy after a non-cardioembolic stroke. Our timeline from the trial record and announcements:
Our timeline, with day counts to the Nov. 9 approval: OCEANIC-STROKE enrolled its first patient on Jan. 26, 2023 (1,383 days). OCEANIC-AF was stopped on Nov. 19, 2023 (1,086 days). OCEANIC-STROKE reached primary completion on Oct. 23, 2025 (382 days). The NEJM paper appeared on April 15, 2026 (208 days). Bayer announced on May 18, 2026, that the FDA had granted Priority Review (175 days). China's approval was reported Oct. 26, 2026 (14 days).
The commercial expectations have shrunk along the way. Bayer cut its peak sales forecast for asundexian to 1 billion euros from about 5 billion euros, pharmaphorum reported.
Who else is testing factor XI drugs?
Asundexian will not be alone for long if the pipeline delivers. To size it, we searched ClinicalTrials.gov on Nov. 10 for phase 3 trials of the four factor XI or XIa drugs with late-stage programs and counted 17 registered studies.
Our count of phase 3 factor XI(a) trials on ClinicalTrials.gov: Asundexian (Bayer), two trials: OCEANIC-STROKE completed and OCEANIC-AF terminated. Milvexian (Janssen with Bristol Myers Squibb), three trials: LIBREXIA-ACS completed without benefit, while LIBREXIA-STROKE (12,523 patients, estimated primary completion Oct. 15, 2026) and LIBREXIA-AF (20,284 patients against apixaban, estimated primary completion Dec. 8, 2026) are active but no longer recruiting. Abelacimab (Anthos Therapeutics with Novartis), three trials: LILAC-TIMI 76 in high-risk atrial fibrillation patients is recruiting, and two cancer-associated venous thromboembolism trials were terminated by sponsor decision. Regeneron's antibodies cenvacibart (REGN7508) and REGN9933, nine trials, eight of them recruiting, in venous thromboembolism, atrial fibrillation and vascular outcomes. The ninth, ROXI-DAISEN, would test cenvacibart for secondary stroke prevention in 6,106 patients and lists an estimated start of Nov. 20, 2026. We excluded a second, not-yet-recruiting LILAC registration under Novartis that lists an estimated start in December 2027.
The milvexian acute coronary syndrome result is a reminder that the class is not uniformly positive, much as the Lp(a) and IL-6 trials presented at the American Heart Association meeting showed that a drug can hit its target and still miss on outcomes. In LIBREXIA-ACS, major adverse cardiovascular events occurred in 5.4 percent on milvexian and 5.1 percent on placebo (HR 1.05; 95% CI, 0.91 to 1.21), HCPLive reported from the ESC Congress presentation on Aug. 28. LIBREXIA-STROKE, testing the same question asundexian just answered, is the trial to watch next.
What should practices do now?
Andrew Russman, a Cleveland Clinic stroke neurologist and OCEANIC-STROKE investigator, told Cleveland Clinic's physician publication that “asundexian significantly lowered patients’ ischemic stroke risk without an increase in major bleeding risk.” The label's subgroup signals in older patients and in the first 90 days are the caveat to set beside that.
Stroke programs should decide now where asundexian fits in discharge order sets for non-cardioembolic stroke and high-risk TIA, and who checks for atrial fibrillation before it is started, since the drug is not approved for it. Pharmacy teams should flag carbamazepine and other combined P-gp and strong CYP3A4 inducers, and hepatic impairment. Procedural services need the 24-hour hold rule written into their pre-procedure anticoagulation protocols. Expect prior authorization once payers set coverage, and watch for the LIBREXIA-STROKE readout, which by its registry dates could come within months.
Reported, fact-checked and edited by The Script Pad's editorial staff. See How we use AI.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
